Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 3, 2009, Pages 222-232

  Proctor, S J ^a   Wilkinson, J ^a   Sieniawski, M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Clinical oncology; Elderly; Hodgkin lymphoma

Indexed keywords

BASILIXIMAB; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; LOMUSTINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

AGING; CANCER INCIDENCE; CANCER REGISTRY; CANCER RELAPSE; CANCER STAGING; CLINICAL FEATURE; COMORBIDITY; HODGKIN DISEASE; HUMAN; OVERALL SURVIVAL; POPULATION RESEARCH; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

AGE FACTORS; AGED; COMORBIDITY; FORECASTING; HODGKIN DISEASE; HUMANS; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 67849085186     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.12.007     Document Type: Review

References (64)

1. Stark G.L., Wood K.M., Jack F., et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 119 (2002) 432-440
2. Bosi A., Ponticelli P., Casini C., et al. Clinical data and therapeutic approach in elderly patients with Hodgkin's disease. Haematologica 74 (1989) 463-473
3. Austin-Seymour M.M., Hoppe R.T., Cox R.S., et al. Hodgkin's disease in patients over sixty years old. Ann Intern Med 100 (1984) 13-18
4. Peterson B.A., Pajak T.F., and Cooper M.R. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 66 (1982) 315-319
5. van Spronsen D.J., Janssen-Heijnen M.L., Breed W.P., and Coebergh J.W. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 78 (1999) 315-319
6. Weekes C.D., Vose J.M., Lynch J.C., et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20 (2002) 1087-1093
7. Landgren O., Algernon C., Axdorph U., et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88 (2003) 438-444
8. Levis A., Depaoli L., Urgesi A., et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 79 (1994) 46-54
9. Erdkamp F.L., Breed W.P., Bosch L.J., et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer 70 (1992) 830-834
10. Enblad G., Glimelius B., and Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol 2 (1991) 297-302
11. Kim H.K., Silver B., Li S., et al. Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys 56 (2003) 556-560
12. Specht L., and Nissen N.I. Hodgkin's disease and age. Eur J Haematol 43 (1989) 127-135
13. Guinee V.F., Giacco G.G., Durand M., et al. The prognosis of Hodgkin's disease in older adults. J Clin Oncol 9 (1991) 947-953
14. Engert A., Ballova V., Haverkamp H., et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23 (2005) 5052-5060
15. Ballova V., Ruffer J.U., Haverkamp H., et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 16 (2005) 124-131
16. Levis A., Depaoli L., Bertini M., et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 81 (1996) 450-456
17. Klimm B., Diehl V., and Engert A. Hodgkin's lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park) 21 (2007) 982-990 [discussion 990, 996, 998 passim]
18. Hamlin PA. Treatment of aggressive non-hodgkin's and Hodgkin's lymphoma in older patients. American Society of Clinical Oncology: 2007 Educational Book (2007), American Society of Clinical Oncology, Chicago pp. 295-9
19. Jarrett R.F., Stark G.L., White J., et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 106 (2005) 2444-2451
20. Levis A., Anselmo A.P., Ambrosetti A., et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15 (2004) 123-128
21. Kolstad A., Nome O., Delabie J., et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 48 (2007) 570-576
22. Klimm B., Eich H.T., Haverkamp H., et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 18 (2007) 357-363
23. Hurria A., Gupta S., Zauderer M., et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104 (2005) 1998-2005
24. Parkin D.M., and Muir C.S. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 120 (1992) 45-173
25. Taylor P.R., Angus B., Owen J.P., Proctor S.J., and Northern Region Lymphoma Group. Hodgkin's disease: a population-adjusted clinical epidemiology study (PACE) of management at presentation. QJM 91 (1998) 131-139
26. Miller T., LeBanc M., and Braziel Rl. Was the bimodal age incidence of Hodgkin's lymphoma a result of mistaken diagnoses of non-Hodgkin's lymphoma?. Blood 100 (2002) 771a [Abstract 3048]
27. Proctor S.J., White J., and Jones G.L. An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme. Eur J Haematol Suppl (2005) 63-67
28. Proctor S.J., Rueffer J.U., Angus B., et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol 13 Suppl. 1 (2002) 133-137
29. Proctor S.J., and Wilkinson J. Extreme Hodgkin's lymphoma: current problem areas. Ann Oncol 17 Suppl. 4 (2006) iv15-iv17
30. Proctor S.J., and Wilkinson J. A web-based study concept designed to progress clinical research for 'orphan' disease areas in haematological oncology in the elderly: the SHIELD programme. Crit Rev Oncol Hematol 61 (2007) 79-83
31. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
32. Ferme C., Eghbali H., Meerwaldt J.H., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357 (2007) 1916-1927
33. Hagemeister F.B. Hodgkin's lymphoma in younger patients: lessons learned on the road to success. Oncology (Williston Park) 21 (2007) 434-440 [discussion 441-2, 445-6]
34. Macpherson N., Klasa R.J., Gascoyne R., et al. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma 43 (2002) 1395-1402
35. Nogova L., Sieniawski M., and Nisters-Backes H. A new BACOPP schedule is feasible and effective in elderly Hodgkin's lymphoma patients-interim results of a multicenter phase II trial of the German Hodgkin Study Group (GHSG). Blood 106 (2005) [Abstract 4735]
36. Bredenfield H., Borchmann P., and Engert A. PVAG-a new regimen in elderly patients with Hodgkin lymphoma. Proceedings of the 10th International Conference on Malignant Lymphoma Edition Lugano, Switzerland. Ann Oncol (2008)
37. Brusamolino E., Castelli G., Pagnucco G., et al. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease. Haematologica 75 (1990) 340-345
38. Brusamolino E., Orlandi E., Canevari A., et al. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 5 (1994) 427-432
39. Lennard A.L., Carey P.J., Jackson G.H., and Proctor S.J. An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemother Pharmacol 26 (1990) 301-305
40. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 18 (2000) 2615-2619
41. Janssen-Heijnen M.L., van Spronsen D.J., Lemmens V.E., et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 129 (2005) 597-606
42. Gomez H., Hidalgo M., Casanova L., et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 16 (1998) 2065-2069
43. Dixon D.O., Neilan B., Jones S.E., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4 (1986) 295-305
44. Yancik R., Wesley M.N., Ries L.A., et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 82 (1998) 2123-2134
45. Piccirillo J.F., Tierney R.M., Costas I., et al. Prognostic importance of co-morbidity in a hospital-based cancer registry. JAMA (2004) 2441-2447
46. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
47. Dittus K., and Muss H.B. Management of the frail elderly with breast cancer. Oncology (Williston Park) 21 (2007) 1727-1734 (discussion 1737,1740 passim)
48. Bergner M. Quality of life, health status, and clinical research. Med Care 27 (1989) S148-S156
49. van Tulder M.W., Aaronson N.K., and Bruning P.F. The quality of life of long-term survivors of Hodgkin's disease. Ann Oncol 5 (1994) 153-158
50. Wettergren L., Bjorkholm M., Axdorph U., and Langius-Eklof A. Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Qual Life Res 13 (2004) 1369-1379
51. Mols F., Vingerhoets A.J., Coebergh J.W., et al. Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: a population-based study. Eur J Cancer 42 (2006) 2794-2801
52. Hjermstad M.J., Oldervoll L., Fossa S.D., et al. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer 42 (2006) 327-333
53. Kawiecka-Dziembowska B., Borkowska A., Zurawski B., et al. The assessment of temperament, quality of life and intensity of depressive symptoms in patients with Hodgkin's disease in different stages of the illness. Psychiatr Pol 39 (2005) 679-690
54. Lawton M.P., and Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9 (1969) 179-186
55. Katz S., and Akpom C.A. A measure of primary sociobiological functions. Int J Health Serv 6 (1976) 493-508
56. Ferrucci L., Guralnik J.M., Cavazzini C., et al. The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol 46 (2003) 127-137
57. Casasnovas R.O., Mounier N., Brice P., et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25 (2007) 1732-1740
58. Kelley T.W., Pohlman B., Elson P., and Hsi E.D. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 128 (2007) 958-965
59. Proctor S.J., and Wilkinson J. Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin's lymphoma. In: Baccarani M., Pileri S., and Zinzani P.L. (Eds). Its time to take care of T-cell lymphomas (2006), Haematologica Reports, Bologna, Italy 32-34
60. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25 (2007) 2764-2769
61. Younes A., Romaguera J., Hagemeister F., et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98 (2003) 310-314
62. Younes A, Fayad LE, Goy A et al. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin Lymphoma: improvement of event free survival (EFS) in all International Prognostic Score (IPS) Groups. 2006 ASH Annual Meeting Abstracts, Part 1. Blood 2006;108:776a.
63. Oki Y., Pro B., Fayad L.E., et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112 (2008) 831-836
64. Omuro A.M., Taillandier L., Chinot O., et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85 (2007) 207-211